Abstract:Eight genetically distinct families of the enzyme carbonic anhydrase (CA, EC 4.2.1.1) were described in organisms allover the phylogenetic tree. They catalyze the hydration of CO2 to bicarbonate and protons, and are involved in pH regulation, chemosensing and metabolism. The 15 α-CA isoforms present in humans are pharmacological drug targets known for decades, their inhibitors being used as diuretics, antiglaucoma, antiepileptic or antiobesity drugs, as well as for the management of acute mountain sickness, idiopathic intracranial hypertension and recently, as antitumor theragnostic agents. Other potential applications include the use of CA inhibitors (CAIs) in inflammatory conditions, cerebral ischemia, neuropathic pain, or for Alzheimer's/Parkinson's disease management. CAs from pathogenic bacteria, fungi, protozoans and nematodes started to be considered as drug targets in recent years, with notable advances registered ultimately. CAIs have a complex multipharmacology probably unique to this enzyme, which has been exploited intensely but may lead to other relevant applications in the future, due to the emergence of drug design approaches which afforded highly isoform-selective compounds for most α-CAs known to date. They belong to a multitude of chemical classes (sulfonamides and isosteres, (iso)coumarins and related compounds, mono- and dithiocarbamates, selenols, ninhydrines, boronic acids, benzoxaboroles, etc). The polypharmacology of CAIs will also be discussed since drugs originally discovered for the treatment of non-CA related conditions (topiramate, zonisamide, celecoxib, pazopanib, thiazide and high-ceiling diuretics) show efective inhibition against many CAs, which led to their repurposing for diverse pharmacological applications. Significance Statement Carbonic anhydrase inhibitors have multiple pharmacologic applications as diuretics, antiglaucoma, antiepileptic, antiobesity, anti-acute mountain sickness, anti-idiopathic intracranial hypertension and as antitumor drugs. Their use in inflammatory conditions, cerebral ischemia, neuropathic pain, or neurodegenerations started to be investigated recently. Parasite carbonic anhydrases are also drug targets for antiinfectives with novel mechanisms of action which can by pass drug resistance to commonly used such agents. Drugs discovered for the management of other conditions that effectively inhibit these enzymes exert interesting polypharmacologic effects.

Carbonic anhydrase hybrid nanoflowers: From facile synthesis to their therapeutic prospects; the known, the unknown and the future

Carbonic anhydrases: Moiety appended derivatives, medicinal and pharmacological implications

Immobilization of Carbonic Anhydrase by Embedding and Covalent Coupling into Nanocomposite Hydrogel Containing Hydrotalcite

Synthesis and Characterization of Poly(acrylic Acid‐co‐acrylamide)/hydrotalcite Nanocomposite Hydrogels for Carbonic Anhydrase Immobilization

Synthetic hydrogel polymer nanoparticles as a structural mimic of carbonic anhydrase

Biomineralization of carbon dioxide by carbonic anhydrase

Chemistry of heterocycles as carbonic anhydrase inhibitors: A pathway to novel research in medicinal chemistry review

Poly(acrylic acid)/Hydrotalcite Nanocomposite Hydrogels:Preparation,and Preliminary Immobilization Studies of Carbonic Anhydrase

Multi- and poly-pharmacology of carbonic anhydrase inhibitors

Developing a hybrid carbonic anhydrase with exceptional high temperature and alkaline environments resistance for efficient CO 2 capture from air

Phthalazine sulfonamide derivatives as carbonic anhydrase inhibitors. Synthesis, biological and in silico evaluation

Carbon dioxide sequestration with carbonic anhydrase nanobiocatalysts: a review

Biomedical applications of prokaryotic carbonic anhydrases: an update

Carbonic anhydrase inhibition/activation: trip of a scientist around the world in the search of novel chemotypes and drug targets

Click chemistry approaches for developing carbonic anhydrase inhibitors and their applications

Carbonic anhydrase and bacterial metabolism: a chance for antibacterial drug discovery

Recent Advances in the Development of Molecular Probes for Targeting Carbonic Anhydrases

Effect of Carbonic Anhydrase on Enzymatic Conversion of CO2 to Formic Acid and Optimization of Reaction Conditions

Carbonic anhydrase encapsulation using bamboo cellulose scaffolds for efficient CO2 capture and conversion

Bio-Inspired Iron-Based Carbonic Anhydrase Mimic for CO 2 Hydration and Conversion

Design, Synthesis, Kinetic Analysis and Pharmacophore-Directed Discovery of 3-Ethylaniline Hybrid Imino-Thiazolidinone as Potential Inhibitor of Carbonic Anhydrase II: An Emerging Biological Target for Treatment of Cancer